» Articles » PMID: 32857259

Magnetic Resonance Imaging Analysis of Liver Fibrosis and Inflammation: Overwhelming Gray Zones Restrict Clinical Use

Overview
Publisher Springer
Date 2020 Aug 29
PMID 32857259
Citations 5
Authors
Affiliations
Soon will be listed here.
Abstract

Magnetic resonance (MR) identification and grading of subjects with liver fibrosis and inflammation represents a clinical challenge. MR elastography plays a well-defined role in fibrosis estimation, but its use is not widely available in clinical settings. Given that liver MR is becoming the reference standard for fat and iron quantitation, there is a need to clarify whether there is any role for MR imaging in the concomitant evaluation of fibrosis and inflammation in this setting. This review summarizes the diagnostic estimations of different MR imaging parameters obtained from conventional non-contrast-enhanced multiple b values diffusion-weighted acquisitions, variable flip angles T1 relaxation maps and STIR images. Although some derived parameters have shown a significant correlation to histological scores, a small magnitude of effect with wide overlap across severity grades is the rule. Contrary to fat and iron quantification, the low precision and reproducibility of MR imaging metrics limits its clinical relevance in fibrosis and inflammation assessment. In a sequential clinical approach combining different methodologies, MR imaging has no applicability for ruling-out and low accuracy for ruling-in advanced fibrosis. Thereby, MR elastography remains as the only image method with high diagnostic accuracy for the detection of advanced fibrosis. Until date, inflammation remains in a gray zone where biopsy cannot be replaced, and further investigations are needed. The present review offers an in-depth discuss of the MR imaging diagnostic performance for the evaluation of liver fibrosis and inflammation, highlighting the need for scientific improvements.

Citing Articles

Potential role of predictive models in assessment of liver inflammation in patients with hepatocellular carcinoma: a two-center cohort study.

Xu W, Li B, Gong H, Li J, Yang Z, Liu Y Eur J Med Res. 2024; 29(1):518.

PMID: 39465438 PMC: 11514854. DOI: 10.1186/s40001-024-02116-8.


The Role of the Multiparametric MRI LiverMultiScan in the Quantitative Assessment of the Liver and Its Predicted Clinical Applications in Patients Undergoing Major Hepatic Resection for Colorectal Liver Metastasis.

Chouari T, Merali N, La Costa F, Santol J, Chapman S, Horton A Cancers (Basel). 2023; 15(19).

PMID: 37835557 PMC: 10571783. DOI: 10.3390/cancers15194863.


Secondary Iron Overload and the Liver: A Comprehensive Review.

Pinyopornpanish K, Tantiworawit A, Leerapun A, Soontornpun A, Thongsawat S J Clin Transl Hepatol. 2023; 11(4):932-941.

PMID: 37408825 PMC: 10318281. DOI: 10.14218/JCTH.2022.00420.


Rethinking Liver Fibrosis Staging in Patients with Hepatocellular Carcinoma: New Insights from a Large Two-Center Cohort Study.

Xu W, Li B, Yang Z, Li J, Liu F, Liu Y J Hepatocell Carcinoma. 2022; 9:751-781.

PMID: 35983561 PMC: 9380840. DOI: 10.2147/JHC.S372577.


Subclinical versus advanced forms of alcohol-related liver disease: Need for early detection.

Gomez-Medina C, Melo L, Marti-Aguado D, Bataller R Clin Mol Hepatol. 2022; 29(1):1-15.

PMID: 35430784 PMC: 9845676. DOI: 10.3350/cmh.2022.0017.

References
1.
Pimpin L, Cortez-Pinto H, Negro F, Corbould E, Lazarus J, Webber L . Burden of liver disease in Europe: Epidemiology and analysis of risk factors to identify prevention policies. J Hepatol. 2018; 69(3):718-735. DOI: 10.1016/j.jhep.2018.05.011. View

2.
Asrani S, Kouznetsova M, Ogola G, Taylor T, Masica A, Pope B . Increasing Health Care Burden of Chronic Liver Disease Compared With Other Chronic Diseases, 2004-2013. Gastroenterology. 2018; 155(3):719-729.e4. DOI: 10.1053/j.gastro.2018.05.032. View

3.
Ratziu V, Charlotte F, Heurtier A, Gombert S, Giral P, Bruckert E . Sampling variability of liver biopsy in nonalcoholic fatty liver disease. Gastroenterology. 2005; 128(7):1898-906. DOI: 10.1053/j.gastro.2005.03.084. View

4.
ISHAK K, Baptista A, Bianchi L, Callea F, De Groote J, Gudat F . Histological grading and staging of chronic hepatitis. J Hepatol. 1995; 22(6):696-9. DOI: 10.1016/0168-8278(95)80226-6. View

5.
Bedossa P, Carrat F . Liver biopsy: the best, not the gold standard. J Hepatol. 2008; 50(1):1-3. DOI: 10.1016/j.jhep.2008.10.014. View